Перейти к основному содержанию
AkademIndex

Продукты

Для разработчиков

AkademBaseОткрытый API экосистемы
Обзорная статья

Progress and prospects of early detection in lung cancer

Sean KnightNorth West Lung Centre, University Hospital South Manchester, Manchester, UKPhilip CrosbieCancer Research UK Lung Cancer Centre of Excellence at Manchester and University College LondonHaval BalataNorth West Lung Centre, University Hospital South Manchester, Manchester, UKJakub ChudziakCancer Research UK Manchester InstituteTracy HussellManchester Collaborative Centre for Inflammation Research, University of Manchester, Manchester, UKCaroline DiveCancer Research UK Lung Cancer Centre of Excellence at Manchester and University College London
2017en
ABI

Аннотация

Lung cancer is the leading cause of cancer-related death in the world. It is broadly divided into small cell (SCLC, approx. 15% cases) and non-small cell lung cancer (NSCLC, approx. 85% cases). The main histological subtypes of NSCLC are adenocarcinoma and squamous cell carcinoma, with the presence of specific DNA mutations allowing further molecular stratification. If identified at an early stage, surgical resection of NSCLC offers a favourable prognosis, with published case series reporting 5-year survival rates of up to 70% for small, localized tumours (stage I). However, most patients (approx. 75%) have advanced disease at the time of diagnosis (stage III/IV) and despite significant developments in the oncological management of late stage lung cancer over recent years, survival remains poor. In 2014, the UK Office for National Statistics reported that patients diagnosed with distant metastatic disease (stage IV) had a 1-year survival rate of just 15-19% compared with 81-85% for stage I.

Перевод пока недоступен

Идентификаторы

Цитирования и источники

Цитирований: 2Использованных источников: 0